1. Updates in RA, PsA, and Biosimilars

2. What's New in Rheumatoid Arthritis?

3. What's New in RA Therapies?

4. JAK Inhibitors for RA Educating Patients on New Agents

5. Patient Education and Counseling on New Agents in RA

6. Patient Education Lifestyle Modification for Patients With RA

7. Helping Patients With Cost of Medications

8. Assessing Patients' Quality of Life

9. What's New in Psoriatic Arthritis?

10. Advances in Pharmacologic Therapies in Psoriatic Arthritis

11. Choosing the Appropriate Agent for Patients

12. Education and Counseling on PsA

13. Managing PsA

14. Additional Comorbidities in Patients With PsA

15. Monitoring Disease Activity

16. Concluding Remarks

17. Biosimilars in Rheumatologic Diseases

18. What Are Biosimilars?

19. How Do Biosimilars Compare With the Original Biologic?

20. Safety and Immunogenicity of Biosimilars Compared With Biologics

21. Biosimilars Are Not the Same as Generics

22. Biosimilars in Rheumatology

23. Educating Patients on Biosimilars

24. Introducing Biosimilars to Patients

25. Abbreviations